#CTICares: Our #Diversity, #Equity, #Inclusion, & #Belonging (DEIB) Council embodies CTI's commitment to recognizing & embracing a multitude of perspectives, backgrounds, & experiences. At CTI, we're dedicated to #MovingMedicineForward & uniting our unique #CTIFamily through our global #DEIB committee. #ThinkGlobalActLocal: Learn how CTI thinks globally & acts locally at https://www.ctifacts.com/
CTI Clinical Trial and Consulting Services’ Post
More Relevant Posts
-
#MovingMedicineForward: Congratulations to Poornima Gopalan, CTI’s Clinical Research Associate, for being named the 2024 NGLA Winner in Medical & Healthcare Services! CTI proudly sponsored the 2024 Next Generation Leader Awards (NGLA) hosted by the Northern Kentucky Chamber of Commerce. #ThinkGlobalActLocal: These awards honor individuals active in the community & dedicated to improving the #NKY region!
-
-
#MovingMedicineForward: Explore the latest breakthrough in the International Journal of Spine Surgery's article on Allogeneic Disco Progenitor Cells & Lumbar Disc Degeneration. This study evaluated the safety & efficacy of injectable disc cell therapy. It concluded a high dose of allogeneic disc progenitor cells significantly improved back pain & disc volume one year after a single injection, with results sustained for two years. We highlight these authors for their dedication to #AdvancingHealthcareSolutions for individuals suffering from back pain. Read more about this exciting development below.
-
CTI’s #ResearchAssociate (RA) program is committed to #MovingMedicineForward through departmental support, community outreach, & nurturing CTI's future workforce. Our team members advance by participating in departmental trainings, contributing to various projects, & pursuing their career goals. Learn more: https://bit.ly/4ctzXKA #ThinkGlobalActLocal: Currently, 7 #RAs have been promoted globally across 6 departments, supporting 58+ clinical trials, mentoring 85+ students through Adopt A Class, & contributing to 24+ projects beyond clinical trials. They’re also active members of CTI’s #DEIB Committee. #CTICares & we anticipate their continued growth & success at CTI!
-
-
-
-
-
+2
-
-
Check out CTI's latest episode of #MovingMedicineForward – The Podcast! In this episode, we dive into #DiversityInClinicalResearch with insights from CTI’s CEO Timothy Schroeder & Board Member William Fitzsimmons. Hear about Fitzsimmons' journey into #ClinicalResearch, the importance of #Diversity in #ClinicalTrials, & strategies to overcome medical mistrust. We also discuss the latest FDA guidance on diversity & CTI’s initiatives to foster inclusive practices. Subscribe to join our discussion on #AdvancingHealthcareSolutions, clinical research, the patient journey, & more. Listen now at: https://bit.ly/4cv5kEt #CTIPodcast: Don’t forget to share, follow, & subscribe so you never miss an episode!
-
#CTICares: We value work-life balance & family time! Did you know? We proudly offer generous #ParentalLeave benefits to all our employees across the globe. Through our supportive work environment, our #CTIFamily can prioritize work-life balance, allowing us to leave a lasting impact in the #CRO industry to #MoveMedicineForward! Discover how CTI makes a global difference: www.ctifacts.com
-
Happy #IndependenceDay from our #CTIFamily! Today, we celebrate the courage of our founding fathers & honor the sacrifices made for our freedom. Thanks to their bravery, we continue #MovingMedicineForward & #AdvanceHealthcareSolutions.
-
-
#MovingMedicineForward: Congratulations to our friends at Asklepios BioPharmaceutical, Inc. (AskBio) on opening enrollment for REGENERATE-PD, a Phase 2 trial of AB-1005 in Parkinson’s disease. #AskBio, a #GeneTherapy company, has encouraging results from their Phase 1b study & 18-month data, promoting the survival of vulnerable brain cells affected by #Parkinson’s. We highlight AskBio for their commitment to advancing potential #ParkinsonsDisease research! Learn more about their research in the article linked below.
Today we announced the initiation of recruitment to REGENERATE-PD, a Phase 2 clinical study assessing the efficacy and safety of AB-1005, an investigational #genetherapy for the treatment of moderate-stage Parkinson’s disease. More than 10 million people worldwide suffer from Parkinson’s disease, with approximately 1 million living in the United States. #AskBio is dedicated to advancing research and embracing cutting-edge science to explore gene therapy solutions for this debilitating disease. For Medical Media – Read our press release here: https://lnkd.in/g478gFVH #ParkinsonsDisease
-
-
#ThinkGlobalActLocal: For Brain & #AlzheimersAwareness Month, we're raising global awareness & supporting the millions affected by #Alzheimer's disease & other #Dementias worldwide. #CTICares: We’re committed to #MovingMedicineForward, leading the way in #Neurology research. CTI’s Clinical Research Center (CRC) has conducted 16+ trials in this area, including Alzheimer's & Mild Cognitive Impairment. With our expertise in caring for complex & critically ill patients, let's shape the future of #NeurologyResearch together!
-
-
#ThinkGlobalActLocal: We're ready to put #Covington on the global #LifeSciences map! CTI is proud to join the OneNKY Alliance Center, a cutting-edge hub for Covington Life Sciences Partners & ten #NKY growth organizations. We celebrated a major milestone with the Topping Out ceremony, placing the final steel beam. #MovingMedicineForward: Opening Summer 2025, our state-of-the-art wet lab will occupy 15,000 sqft on the 2nd floor, housing several regional #biotech companies. We're excited to contribute to this achievement & move towards a unified #OneNKY!
-
